These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7687111)

  • 1. Persistence of antibody at 18 months following vaccination of young Gambian infants with PRP-OMPC Haemophilus influenzae type b conjugate vaccine.
    Mulholland EK; Todd J; Rowe M; Campbell H; Byass P; Vella PP; Ahonkhai VI; Greenwood BM
    Ann Trop Paediatr; 1993; 13(2):153-8. PubMed ID: 7687111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants.
    Mulholland EK; Byass P; Campbell H; Fritzell B; Greenwood AM; Todd J; Greenwood BM
    Ann Trop Paediatr; 1994; 14(3):183-8. PubMed ID: 7825990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses.
    Calandra GB; Lukacs LJ; Jonas LC; Santosham M; Ward JI; Greenberg DP; Daum RS; Matthews H; Vella PP; Ryan JL
    Vaccine; 1993; 11 Suppl 1():S58-62. PubMed ID: 8447178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV
    J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.
    Granoff DM; Rathore MH; Holmes SJ; Granoff PD; Lucas AH
    Vaccine; 1993; 11 Suppl 1():S46-51. PubMed ID: 8447176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Wong VK; Quagliata R; Adler R; Kim KS
    Am J Dis Child; 1991 Jul; 145(7):742-5. PubMed ID: 2058604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An enzyme-linked immunosorbent assay for quantitation of Haemophilus Influenzae type b polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera.
    Dolan KT; Staub JM; Schofield TL; Ahonkhai VI; Ellis RW; Vella PP
    J Immunoassay; 1991; 12(4):543-64. PubMed ID: 1806588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.
    Santosham M; Hill J; Wolff M; Reid R; Lukacs L; Ahonkhai V
    Pediatr Infect Dis J; 1991 Feb; 10(2):113-7. PubMed ID: 2062601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs. HbOC vaccine.
    Reid R; Santosham M; Croll J; Thompson C; Newcomer W; Siber GR
    Pediatr Infect Dis J; 1993 Oct; 12(10):812-5. PubMed ID: 8284116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of 7- to 15-month-old infants to sequential immunization with Haemophilus influenzae type b-CRM197 conjugate and polysaccharide vaccines.
    Rothstein EP; Schiller RP; Girone JA; Hipp TJ; Souder RL; Bernstein HH; Madore DV; Johnson CL; Smith DH
    Am J Dis Child; 1991 Aug; 145(8):898-900. PubMed ID: 1858727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants.
    Campbell H; Byass P; Ahonkhai VI; Vella PP; Greenwood BM
    Pediatrics; 1990 Jul; 86(1):102-7. PubMed ID: 2113671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age.
    Berkowitz CD; Ward JI; Chiu CE; Marcy SM; Gordon L; Hendley JO; Meier K; Marchant CD; McVerry P
    Pediatrics; 1990 Mar; 85(3):288-93. PubMed ID: 2304781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants.
    Mulholland EK; Ahonkhai VI; Greenwood AM; Jonas LC; Lukacs LJ; Mink CM; Staub JM; Todd J; Vella PP; Greenwood BM
    Pediatr Infect Dis J; 1993 Aug; 12(8):632-7. PubMed ID: 8414774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in young infants.
    Ambrosino DM; Sood SK; Lee MC; Chen D; Collard HR; Bolon DL; Johnson C; Daum RS
    Pediatr Infect Dis J; 1992 Oct; 11(10):855-9. PubMed ID: 1408486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of Haemophilus influenzae type b-meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age.
    Shehab ZM; Azimi P; Asmar BI; Dunphy MG; Ayoub EM; Dajani AS
    Scand J Infect Dis; 1991; 23(6):763-9. PubMed ID: 1815340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.